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Abstract The MitraClip system is a device for percuta-
neous edge-to-edge reconstruction of the mitral valve in
patients with severe mitral regurgitation who are deemed at
high risk for surgery. Studies have underlined the therapeu-
tic benefit of the MitraClip system for patients at extreme
and high risk for mitral valve surgery, suffering from either
degenerative or functional mitral regurgitation. The Mitra-
Clip procedure shows low peri-procedural complication
rates, and a significant reduction in mitral regurgitation, as
well as an improvement in functional capacity and most im-
portantly quality of life. It hereby widens the spectrum of
mitral valve repair for the Heart Team. The current review
underscores the efficacy of the procedure and describes the
technique to simplify the procedure.
Keywords MitraClip · Mitral regurgitation · Percutaneous
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Introduction
The MitraClip (Abbott Laboratories, Menlo Park, Califor-
nia, USA) is a catheter-based technology that is similar to
the Alfieri technique in that it connects the middle scal-
lops of the anterior and the posterior leaflet of a regurgitant
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mitral valve. The data of the EVEREST (Endovascular
Valve Edge-to-Edge Repair Study) trials [1, 2] and results
of registries [3] demonstrate that the MitraClip procedure
is feasible and safe. Procedural success has been shown to
increase with operator experience [4].
A large prospective, nonrandomised European study,
ACCESS-EU (the Amsterdam Center for Contemporary
European Studies – A Two-Phase Observational Study of
the MitraClip System in Europe) found 81.8% survival at
1 year and 78.9% freedom from severe mitral regurgitation
(MR) [5]. Data from the GRASP (Getting Reduction of
Mitral Insufficiency by Percutaneous Clip Implantation)
registry at 30 days and 1 year showed promising results:
freedom from the same composite endpoint of death,
surgery, or severe MR in 75.8% of 117 treated patients
at 1 year, and a 3.4% MAE rate at 30 days [6]. A meta-
analysis reviewing 16 studies came to similar conclusions,
documenting a low adverse event profile and only 14.7%
of patients demonstrating severe MR at 1 year [7].
Several ongoing trials will help clarify the role of Mitra-
Clip therapy in the treatment of functional MR. The COAPT
trial (Clinical Outcomes Assessment of MitraClip Percuta-
neous Therapy), a prospective, randomised, parallel con-
trolled study, is currently enrolling patients with severe
functional MR and heart failure (left ventricular ejection
fraction 20–50%). A similar study, the RESHAPE-HF trial
(Randomized Study of the MitraClip Device in Heart Fail-
ure Patients With Clinically Significant Functional Mitral
Regurgitation), is enrolling patients with severe functional
MR and a left ventricular ejection fraction of 15–40%,
deemed non-surgical candidates who will be randomised
to MitraClip therapy versus medical management.
In this review we describe the technical aspects of the
MitraClip procedure.
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Fig. 1 Components of the
MitraClip system (Images pro-
vided and adapted from Abbott
Laboratories, Menlo Park, Cali-
fornia, USA)
Pre-procedural planning
Planning for the clip procedure requires definition of the
mitral valve morphology and the specific pathology causing
regurgitation. The depth/distance to the coaptation point of
valve leaflets is crucial to determine the appropriate clip-
landing site, but valve pathophysiology dictates the ideal
transseptal puncture point [8].
Eligibility criteria
To guarantee safe positioning of the clip, anatomical eli-
gibility criteria are recommended. A coaptation length of
>2 mm, a coaptation depth of <11 mm, and in the case of
degenerative disease, a flail gap of <10 mm and a flail width
of <15 mm are favourable [8]. The MitraClip system con-
sists of a steerable guide catheter that is introduced using
the transfemoral route, and by echocardiographic guiding,
transseptally into the left atrium. The clip delivery system
can be introduced through the guide catheter (Fig. 1).
Determination of the morphology
The mitral valve morphology and the cause of MR should
be assessed in detail by transoesophageal echocardiography
(TEE), as suitable mitral valve morphology is essential to
a successful MitraClip procedure. Transthoracic echocar-
diography is used to assess MR severity, but TEE is also
useful to confirm the initial TTE findings [9].
Characterisation of valve pathology is important for pre-
procedural planning. Degenerative valves causing signifi-
cant MR often have substantial portions of the leaflet that
are either flail or prolapsed. Patients with a flail or prolapse
distance greater than 1 cm width along the line of coapta-
tion or greater than 1 cm into the left atrium do not meet
the criteria for clip procedure and are likely to have poor
procedural success [10].
Assessment of the subvalvular apparatus and chordae is
also important since the extended arms of the clip are easily
entangled within these structures. Short chordae or unusual
angles of chordae usually portend trouble and warrant care-
ful avoidance when possible [10, 11].
Integration of 2D/3D TEE and fluoroscopy for
MitraClip procedure
Two- and three-dimensional (2D/3D) TEE is used for guid-
ance during the MitraClip procedure. Three-dimensional
TEE provides en face views of the mitral valve, thus fa-
cilitating the assessment of mitral valve morphology and
pathology, which is important for patient selection. De-
livery catheters, wires, devices, and target structures can
be visualised in one single view and in relation to each
other, thus optimising transseptal puncture, steering of the
delivery catheter in a 3D space (left atrium) towards the mi-
tral valve and good MitraClip positioning perpendicular to
the line of coaptation in the middle segments of the mitral
valve.
Biner et al. [10] demonstrated that the usage of 2D
and 3D TEE in combination is associated with a remark-
able 28% reduction in procedure times. Fluoroscopy pro-
vides additional helpful information on the positioning and
distance for delivery catheter advancement and MitraClip
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Fig. 2 The puncture site is evaluated using TEE in a 4-chamber view,
and the ‘tenting’ of the atrial septum can be seen as the transseptal
needle is pushed against it, ideally in the superior and posterior part
of the interatrial septum with the aim of obtaining adequate working
space and distance above the mitral annulus
opening, orientation, and the final release of the device on
the leaflets, most notably when a second MitraClip is im-
planted.
The MitraClip procedure is divided into the following
steps: 1) Transseptal puncture; 2) Advancement of the
steerable guide catheter into the left atrium; 3) Advance-
ment of the clip delivery system into the left atrium and
positioning of the MitraClip below the mitral valve leaflets;
and 4) Grasping of the leaflets, assessment of the result and
clip release.
Transseptal puncture
Transseptal puncture represents one of the most important
aspects of the MitraClip procedure. The optimal puncture
site is located superiorly and posteriorly in the interatrial
septum and three TEE planes are used to determine the
correct site: a short-axis view at the base for anterior-pos-
terior orientation, a bi-caval view for superior (cranial)-
caudal (inferior) orientation, and a four-chamber view to
direct the height above the mitral valve. The position of
the BRK transseptal needle (St. Jude Medical, Inc, St Paul,
Minnesota, USA) can be seen by a tent-like indentation of
the interatrial septum (‘tenting’). Thereby, the tip of the
‘tent’ points towards the left atrium. With a satisfactory
posterior and superior location, the height above the valve
is assessed in a four-chamber view (Fig. 2). The site of op-
timal transseptal puncture is different for degenerative and
functional MR. In degenerative disease (e. g. prolapse), the
puncture site needs to be 4–5 cm above the mitral annulus
Fig. 3 Steering and positioning of the MitraClip delivery system in
the left atrium. The Clip Delivery System (CDS) is advanced until
its tip is even with the guide tip under fluoroscopic guidance. The
CDS is further advanced until the guide radiopaque tip ring marker
is centred between the sleeve alignment markers with confirmation on
fluoroscopy (straddling)
to guarantee enough space for adequate catheter and Mitra-
Clip manoeuvring. In contrast, in cases of functional MR,
the line of coaptation is usually below the plane of the mitral
annulus due to extensive tethering. Therefore, the puncture
site in these patients needs to be more inferior and closer to
the annular plane (about 3.5 cm above the annular plane).
Introduction of steerable guide catheter into the
left atrium
The steerable guide catheter with the dilator is gently ad-
vanced into the left atrium over an Amplatz extra stiff wire
(placed in the left upper pulmonary vein) under fluoroscopic
and TEE guidance. The dilator can be easily identified by
a cone-shaped tip and a typical echogenic appearance of
ridges on the catheter system. A radiopaque echo bright
double ring characterises the tip of the guide catheter. The
advancement of the steerable guide catheter should be care-
fully visualised under continuous 2D/3D TEE, and fluoro-
scopic monitoring to avoid injuries of the free left atrial
wall. Once the catheter is safely placed in the left atrium,
the Amplatz extra stiff wire is retrieved first, followed by
the dilator.
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Fig. 4 3D en face view allows
to determine when the clip is
adequately positioned above the
middle segments of the mitral
valve and whether orientation
is perpendicular to the line of
mitral valve coaptation
KEY MESSAGE The MitraClip technique has emerged as an option for mitral repair in high-risk surgical patients. 
Data from a variety of sources demonstrate that the MitraClip system is an effective and safe treat-
ment in high-risk patients. The learning curve associated with the MitraClip implantation suggests 
this therapy should be per-formed in centres of excellence with recognised surgical and structural 
expertise in mitral valve pathologies
Advancement of the clip delivery system into the
left atrium and positioning of the MitraClip below
the mitral valve leaflets
The clip delivery system is advanced via the steerable guide
catheter under fluoroscopic guidance directed toward the
left upper pulmonary vein. TEE is additionally necessary
to ensure that the tip of the steerable guide catheter remains
across the interatrial septum and that the delivery system
with the clip at the tip does not cause injury to the free left
atrial wall.
As the clip delivery system carefully exits the sheath it is
required that the markers in the system straddle the sheath
markers before the clip can be moved toward the mitral
valve (Fig. 3).
To position the clip delivery system above the mitral
valve, a posterior torque of the steerable guide catheter and
simultaneous medial deflection of the clip delivery system
accompanied by retraction of the whole system are required.
These steps are done in our centre under complete fluoro-
scopic guidance. After bypassing the pulmonary ridge and
the left atrial appendage, a gentle anterior rotation of the
clip delivery system accompanied with a simple lateral ro-
tation brings the clip above the mitral valve. The aim of
this manoeuver is to direct the clip in a horizontal direction
as seen in the postero-anterior view fluoroscopically.
Medial-lateral clip adjustments are monitored in 3D en
face view and anterior-posterior adjustments in an orthog-
onal mid-oesophageal long-axis (LVOT) view. To achieve
good clip alignment, both arms of the opened clip can be
visualised in full length in the long-axis view. The tip of the
clip should be directed towards the largest proximal isove-
locity surface area (PISA). A single 3D en face view allows
to determine when the clip is adequately positioned above
the middle segments of the mitral valve and whether orien-
tation is perpendicular to the line of mitral valve coaptation
(Fig. 4).
In the routine practice, it is recommended to pass the
opened clip into the left ventricle [12]. In our experience,
passing the mitral valve with an opened clip will require
reassessment of the orientation of the clip again as the clip
may rotate during translation from the left atrium to the
left ventricle prolonging the procedure [13]. We prefer to
advance the clip closed at the site of the regurgitant jet
under the mitral leaflets in the LVOT view under breath-
holding.
A correct orientation of the MitraClip, with perpendicu-
lar alignment to the line of coaptation, verifying that both
mitral leaflets are freely moving above the clip arms, is
crucial for a successful grasp of the mitral valve leaflets.
To shorten the time of the procedure, we depend on the
orientation of the clip above the mitral valve using 3D-TEE
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Fig. 5 After grasping of the leaflets, leaflet capture is evaluated by
lowering the gripper and partially closing the clip to secure leaflet in-
sertion
(Fig. 4) comparing it with the position of the clip fluoro-
scopically. Moreover, it is of outmost importance to find
the corresponding view in 2D-TEE, where both arms of the
clip are visible above the mitral valve. By doing this we
define the correct angle in 2D-TEE in which we have to
gasp the anterior and posterior leaflet in the PISA. This is
the best and most simple way to ensure safe clipping with
proper perpendicular alignment to the line of coaptation in
the regurgitant area with no risk of valve distortion.
Grasping of the leaflets, assessment of the result
and clip release
Once the MitraClip is in a satisfactory position, grasping
of the leaflets as they are captured in between the clip arms
and the gripper is usually monitored using a 2D LVOT
view. It is recommended to do this with the help of a short
breath-hold, controlled by the accompanying anaesthetist.
Multiple planes are useful for assessment of proper leaflet
insertion into the MitraClip. The insertion of the posterior
leaflet is commonly best seen in the LVOT view, and the
insertion of the anterior leaflet in the four-chamber view.
The intercommissural view can add information such as
entrapped chordae tendinae.
After grasping of the leaflets, leaflet capture is evaluated
by lowering the gripper and partially closing the clip to
secure leaflet insertion (Fig. 5). Formation of the double-
barrelled orifice is confirmed with an en face view to make
sure that each orifice is approximately the same size.
Before and after the implantation of each clip, it is nec-
essary to evaluate the grade of regurgitation and stenosis of
the mitral valve, and in addition, the morphological result
after clip placement [12].
Residual MR can easily be detected by colour Doppler.
However, for quantification, it has to be taken into consid-
eration that the area of colour jets is larger with multiple
jets, which commonly occurs after a MitraClip is implanted
(due to the addition of multiple jet areas), than if there is
a single jet [14]. This may potentially lead to overestimat-
ing residual MR in patients with multiple jets. To overcome
this problem, we recommend the measurement of the pres-
sure curves in the left atrium to measure the height of the
V-wave before the procedure and compare it with the pres-
sure curves after implantation of the MitraClip. This gives
us an idea about the improvement of the degree of the MR.
Left ventricular angiography may also help in evaluation
the severity of the residual MR. On the other hand, angio-
graphic MR grading may be inaccurate if the catheter is
entrapped in the chordae tendineae, if insufficient contrast
is used to opacify the left ventricle and left atrium, or in
the presence of arrhythmias [15].
Implantation of additional MitraClips
Our group has already proven that an optimal correction
of MR after MitraClip placement should be advocated to
optimise the benefits of the procedure and minimise the
risk of adverse outcomes. As residual MR after MitraClip
is associated with higher mortality than that for patients
without MR [16].
The orientation of the second clip is mostly done fluoro-
scopically without the use of echocardiography and should
be aligned as parallel as possible to the first clip.
During advancement of the MitraClip from the left
atrium into the left ventricle under breath-holding, the clip
should be closed to avoid any interference or entanglement
with the chordae tendineae then re-opened in the left ven-
tricle. Folding of leaflet tissue between two MitraClips
should be avoided as this may cause uncorrectable residual
MR [12].
Conclusion
The MitraClip procedure is rapidly evolving as an impor-
tant option among the current therapies for MR. The safety
profile of this device appears to be good and data from ex-
perienced centres have shown that reduction of the severity
of MR is achievable in almost all patients with low in-hos-
pital complications and significant clinical improvement.
Our simplified step-by-step approach helps us a lot.
Patients with moderate to severe or severe MR and suit-
able anatomical characteristics must be properly defined to
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ensure optimal clinical outcomes. In addition, TEE plays
the major role in guidance of the procedure and in follow-
up.
New technologies that synchronise echocardiographic
and fluoroscopic imaging could potentially simplify and
optimise procedural guidance, improve the degree of MR
reduction, and enhance safety as well as shorten the dura-
tion of both fluoroscopy and the procedure time.
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